<DOC>
	<DOCNO>NCT01583920</DOCNO>
	<brief_summary>Radiation therapy consider standard treatment option management localized prostate cancer . Among 20-30 % recur , proportion present isolate local recurrence , mean distant metastasis . If leave untreated , may serve source subsequent metastasis . Salvage option available isolated local recurrence include ; temporary permanent implantation radioactive seed prostate , complete removal prostate gland , use low temperature treat disease , high frequency ultrasound treat disease . There risks complication associate treatment , presently consensus treatment best . Therefore , aim pilot study look feasibility toxicity focal treatment prostate use temporary implantation radioactive seed prostate investigator hope less since entire prostate treat .</brief_summary>
	<brief_title>Focal Salvage HDR Brachytherapy Treatment Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Biopsy confirm locally recurrent prostate adenocarcinoma &gt; 30months completion radiotherapy stereotactic transperineal biopsy Staging T2 weight , DWI DCEMRI demonstrate solitary recurrence confine prostate , correlate stereotactic transperineal biopsy American Urological Association Symptom Index Score ( ie . IPSS ) &lt; 15 Baseline ( post radiotherapy ) serum PSA &lt; 10 ng/mL Prostate volume measure transrectal ultrasound ( TRUS ) &lt; 50cc ECOG performance status 01 Prior radiotherapy prostate exceed 78Gy ( 2Gy fraction ) Any follow prior therapy : transurethral resection prostate ( TURP ) , radionuclide ( permanent temporary implantation ) prostate brachytherapy , prostatectomy prostatic cryosurgery , HIFU ( hiintensity focus ultrasound ) , bilateral orchiectomy , chemotherapy prostatic carcinoma Evidence castrate resistance ( define PSA &gt; 3 ng/mL testosterone &lt; 1.7 nmol/L ) . Patients could combine androgen blockade initial radiotherapy exclude start due PSA progression .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>prostatic neoplasm</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>salvage therapy</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>